Partners Capital Investment Group LLP Sells 161,597 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO)

Partners Capital Investment Group LLP decreased its position in Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) by 63.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 93,248 shares of the company's stock after selling 161,597 shares during the quarter. Partners Capital Investment Group LLP's holdings in Allogene Therapeutics were worth $199,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of ALLO. SG Americas Securities LLC raised its position in shares of Allogene Therapeutics by 252.7% during the third quarter. SG Americas Securities LLC now owns 46,967 shares of the company's stock worth $132,000 after purchasing an additional 33,651 shares during the period. Exchange Traded Concepts LLC raised its position in shares of Allogene Therapeutics by 25.5% during the third quarter. Exchange Traded Concepts LLC now owns 60,675 shares of the company's stock worth $170,000 after purchasing an additional 12,328 shares during the period. Creative Planning raised its position in shares of Allogene Therapeutics by 108.7% during the third quarter. Creative Planning now owns 61,396 shares of the company's stock worth $172,000 after purchasing an additional 31,984 shares during the period. Private Advisor Group LLC acquired a new stake in shares of Allogene Therapeutics during the third quarter worth $34,000. Finally, China Universal Asset Management Co. Ltd. raised its position in shares of Allogene Therapeutics by 64.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 40,219 shares of the company's stock worth $113,000 after purchasing an additional 15,690 shares during the period. Institutional investors and hedge funds own 83.63% of the company's stock.

Insider Transactions at Allogene Therapeutics

In related news, EVP Zachary Roberts sold 27,199 shares of the firm's stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $1.78, for a total transaction of $48,414.22. Following the completion of the sale, the executive vice president now directly owns 488,054 shares of the company's stock, valued at $868,736.12. This trade represents a 5.28 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Timothy L. Moore sold 14,746 shares of the firm's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $1.71, for a total value of $25,215.66. Following the sale, the insider now directly owns 250,713 shares of the company's stock, valued at $428,719.23. This represents a 5.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 71,067 shares of company stock valued at $131,959. Corporate insiders own 24.30% of the company's stock.

Wall Street Analysts Forecast Growth

ALLO has been the topic of a number of recent analyst reports. William Blair reaffirmed an "outperform" rating on shares of Allogene Therapeutics in a research report on Thursday, November 14th. HC Wainwright reissued a "buy" rating and set a $9.00 price target on shares of Allogene Therapeutics in a research report on Friday, November 8th. Finally, Piper Sandler dropped their price target on Allogene Therapeutics from $11.00 to $9.00 and set an "overweight" rating on the stock in a research report on Thursday, November 14th. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, Allogene Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $9.73.

Allogene Therapeutics Price Performance

Shares of ALLO traded down $0.34 during mid-day trading on Thursday, reaching $2.26. The company had a trading volume of 7,153,935 shares, compared to its average volume of 7,066,495. Allogene Therapeutics, Inc. has a twelve month low of $1.32 and a twelve month high of $5.78. The company's 50-day moving average is $1.96 and its 200-day moving average is $2.37. The company has a market capitalization of $473.86 million, a P/E ratio of -1.45 and a beta of 0.83.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).